These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24716778)

  • 1. Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin.
    Yang LP; Zhang AL; Wang DD; Ke HX; Cheng Q; Wang C
    J Clin Pharm Ther; 2014 Aug; 39(4):442-5. PubMed ID: 24716778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.
    Hsiao SH; Chou CH; Lin WL; Lee EJ; Liao LH; Chang HJ; Yeh PY; Lin CY; Wu TJ
    J Clin Pharm Ther; 2012 Jun; 37(3):296-300. PubMed ID: 22017186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
    Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
    Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin.
    Marshall C; Street A; Galbraith K
    J Infect; 1998 Jul; 37(1):82-3. PubMed ID: 9733391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin.
    Khurana C; de Belder MA
    Postgrad Med J; 1999 Jan; 75(879):41-3. PubMed ID: 10396588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin.
    Hsiao SH; Chang CM; Tsai JC; Lin CY; Liao LH; Lin WL; Wu TJ
    Ann Pharmacother; 2007 May; 41(5):891-4. PubMed ID: 17426073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin-induced Stevens-Johnson syndrome.
    Alexander II; Greenberger PA
    Allergy Asthma Proc; 1996; 17(2):75-8. PubMed ID: 8934797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DRESS Syndrome Caused by Cross-reactivity Between Vancomycin and Subsequent Teicoplanin Administration: A Case Report.
    Miyazu D; Kodama N; Yamashita D; Tanaka H; Inoue S; Imakyure O; Hirakawa M; Shuto H; Kataoka Y
    Am J Case Rep; 2016 Aug; 17():625-31. PubMed ID: 27572807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
    Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
    Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.
    Rybak MJ; Bailey EM; Warbasse LH
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1204-7. PubMed ID: 1384423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early diagnosis is key in vancomycin-induced linear IgA bullous dermatosis and Stevens-Johnson syndrome.
    Jones DH; Todd M; Craig TJ
    J Am Osteopath Assoc; 2004 Apr; 104(4):157-63. PubMed ID: 15127983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.
    Hsiao SH; Chen HH; Chou CH; Lin WL; Liu Yeh PY; Wu TJ
    J Clin Pharm Ther; 2010 Dec; 35(6):729-32. PubMed ID: 21054466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety of teicoplanin and vancomycin.
    Wood MJ
    J Chemother; 2000 Nov; 12 Suppl 5():21-5. PubMed ID: 11131960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome in a juvenile systemic lupus erythematosus patient.
    Cavalcante EG; Guissa VR; Jesus AA; Campos LM; Sallum AM; Aikawa NE; Silva CA
    Lupus; 2011 Nov; 20(13):1439-41. PubMed ID: 21768172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Harr T; French LE
    Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
    Hung SI; Chung WH; Liu ZS; Chen CH; Hsih MS; Hui RC; Chu CY; Chen YT
    Pharmacogenomics; 2010 Mar; 11(3):349-56. PubMed ID: 20235791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety of teicoplanin and vancomycin.
    Wilson AP
    Int J Antimicrob Agents; 1998 May; 10(2):143-52. PubMed ID: 9716291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of teicoplanin and vancomycin.
    Harding I; Sorgel F
    J Chemother; 2000 Nov; 12 Suppl 5():15-20. PubMed ID: 11131959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.